Login
Navigate Fool.com
Will BMY beat
the market?
Community Rating: 4 Stars: Favorite

48.17 0.21 (0.44%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $48.29
Previous Close $47.96
Daily Range $47.48 - $48.48
52-Week Range $39.18 - $57.49
Market Cap $79.5B
P/E Ratio 31.71
Dividend (Yield) $1.44 (2.9%)
Ex-Dividend Date
Dividend Pay Date
04/02/14
05/01/14
Volume 13,265,208
Average Daily Volume 8,732,377
Current FY EPS $1.77

How do you think BMY
will perform against the market?

Top BMY Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

How Much Has Merck Shaken Up the Hepatitis C Race?

Recent data presentations at the EASL conference highlight the emerging competition in hepatitis C.

This Forgotten Pharma Could Be a Hit for Your Portfolio

Roche combines a very deep oncology pipeline with some of the best growth and margins in Pharma

Noteworthy ETF Inflows: XLV, JNJ, AMGN, BMY

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Merck plays catch-up while Bristol-Myers looks global.

Amgen's Conundrum

What will Amgen do with T-VEC and will it be able to compete with Bristol-Myers Squibb's Yervoy, which is already on the market, and Merck's (NYSE: MRK) experimental anti-PD-1 antibody MK-3475.

Is This the Answer to Expensive Hepatitis-C Cures?

A dangerous new competitor for Gilead's miracle hepatitis-C drug, Sovaldi, may be on its way to market.

Merck Shouts "Me, Too!" But Will It Matter?

Merck (MRK) joins Gilead (GILD), Bristol-Myers (BMY), and AbbVie (ABBV) in the race to cure hepatitis C, but Merck may end up trailing the pack.

Stunning Spending Growth Prediction for Hepatitis C

New drugs from Gilead (GILD), Johnson & Johnson (JNJ), Bristol-Myers (BMY), and AbbVie (ABBV) have Express Scripts (ESRX) forecasting spending on hepatitis C drugs will double this year.

Sector Update: Healthcare Shares Mixed in Pre-Market Trade; Pfizer Subsidiary Ends License Deal with

Sector Update: Healthcare Shares Mixed in Pre-Market Trade; Pfizer Subsidiary Ends License Deal with Acura

Sector Update: Healthcare

See More BMY News...

Sector

Healthcare

Industry

Drugs

Bristol-Myers Squibb Co. (BMY) Description

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments. Website: http://www.bms.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks